MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
AtriCure Net Debt 2011-2026 | ATRC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AtriCure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -104 M | -59.2 M | -22.3 M | -118 K | 16.9 M | 11.5 M | 33.4 M | 8.06 M | 2.85 M | 1.37 M | -9.6 M | -24.3 M | -8.44 M | 683 K | -3.29 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.4 M | -104 M | -10.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
17.1 B | $ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | USA |
 |
Repligen Corporation
RGEN
|
-236 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-581 K | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | USA |
 |
Haemonetics Corporation
HAE
|
623 M | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
972 M | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | USA |
 |
Intuitive Surgical
ISRG
|
-3.2 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
27.8 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
-28.4 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
-48.3 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
-8.38 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
Pulse Biosciences
PLSE
|
-73.2 M | $ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
InfuSystem Holdings
INFU
|
33.3 M | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
572 M | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
-154 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
299 M | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
-88.9 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
electroCore
ECOR
|
-53 K | $ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
STERIS plc
STE
|
1.78 B | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
2.26 B | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
-60.6 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
-197 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
West Pharmaceutical Services
WST
|
-566 M | $ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.74 B | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
Glaukos Corporation
GKOS
|
-21.6 M | $ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
ResMed
RMD
|
513 M | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
-9.23 M | - | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
7.55 B | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
-115 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
-7.98 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
2.38 B | $ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
143 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
-3.05 M | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
-2.48 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
276 M | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
-955 K | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
2.46 B | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
15 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
-1.69 M | $ 0.69 | 2.99 % | $ 20.7 M | USA |